(Q45274588)

English

Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Gregory Sutton

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

John Blessing

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Parviz Hanjani

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Paul Kramer

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Gynecologic Oncology Group

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

749-752

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Resection of pulmonary metastases from uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.11.036

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.11.036

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45274588&oldid=2072296919"